skip to content

Mjere ishoda u multiploj sklerozi

Mjere ishoda u multiploj sklerozi

Ne postoji jedinstveno mjerilo za multiplu sklerozu (MS). Ovaj pojmovnik sadržava jednostavna objašnjenja za neke od naziva koji se koriste da bi se odredilo kako se multipla skleroza može mjeriti.

M-HR-00001165

References

  1. Multiple Sclerosis Coalition. The Use Of Disease – Modifying Therapies In Multiple Sclerosis: Principles and Current Evidence Summary. Available at http://www.nationalmssociety.org/getmedia/1e64b96c-9e55-400e-9a64-0cdf5e2d60fe/summaryDMTpaper_-final.Accessed September 2016.

  2. Bermel, RA, et al. The measurement and clinical relevance of brain atrophy in multiple sclerosis. The Lancet Neurology. 2006; 5(2):158 – 170.

  3. Wiendl H, Meuth SG. Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs. 2015;75(9):947-977.

  4. Giovannoni, G, et al. Brain Health: Time Matters in Multiple Sclerosis. 2015; pp 14.

  5. Lublin FD, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014; 83(3):278 – 86.

  6. National MS Society. Functional Systems Score (FSS) and Expanded Disability Status Scale. Available at https://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Functional-Systems-Scores-(FSS)-and-Expanded-DisabAccessed September 2016.

  7. National MS Society. Magnetic Resonance Imaging (MRI). Available at https://www.nationalmssociety.org/Symptoms-Diagnosis/DiagnosingTools/MRIAccessed September 2016.

  8. National MS Society. Multiple Sclerosis Functional Composite (MSFC). Available at https://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Multiple-Sclerosis-Functional-Composite-(MSFC)Accessed September 2016.

  9. MS Society UK. NEDA (no evidence of disease activity). Available at https://mstrust.org.uk/a-z/neda-no-evidence-disease-activityAccessed September 2016.

  10. National MS Society. 9-Hole Peg Test (9-HPT). Available at http://www.nationalmssociety.org/For-Professionals/Researchers/Resources-forResearchers/Clinical-Study-Measures/9-Hole-Peg-Test-(9-HPT)Accessed September 2016.

  11. National MS Society. Paced Auditory Serial Addition Test (PASAT). Available at http://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Paced-Auditory-Serial-Addition-Test-(PASAT).Accessed September 2016.

  12. National MS Society. Managing Relapses. Available at http://www.nationalmssociety.org/Treating-MS/Managing-Relapses.Accessed September 2016.

  13. National MS Society. Timed 25-Foot Walk (T25-FW). Available at http://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Timed-25-Foot-Walk-(T25-FW)Accessed September 2016.

  14. Sethi V, et al. Slowly eroding lesions in multiple sclerosis. Mult Scler. 2017 Mar;23(3):464-472.

Više priča

Pročitajte sve priče

Progresija bolesti u multiploj sklerozi

Većina ljudi s MS-om u određenom trenutku doživi pogoršanje fizičke onesposobljenosti. Kad se to dogodi, vrsta onesposobljenosti i koliko se ona mijenja razlikuju se kod svakog pojedinca.

Ključne spoznaje u vezi s multiplom sklerozom

Razvijene su nove terapije s različitim načinima djelovanja i putovima primjene te su odobrene za RMS. U zemljama diljem svijeta, za liječenje primarno progresivne multiple skleroze sada postoji lijek koji mijenja tijek bolesti.

Povećana očekivanja za oboljele od PPMS-a

Primarno progresivni oblik MS-a, poznat i kao PPMS, znatno onesposobljava ljude jer je prisutna stalna progresija simptoma, koje je katkad teže prepoznati i pripisati MS-u.

Oblici multiple skleroze

Većina osoba s MS-om u početku ima relapsno-remitirajući ili primarno progresivni oblik MS-a prepoznat tijekom postavljanja dijagnoze.